Key result
Low-dose aspirin increased mean gestational age at delivery compared to placebo in women with high-risk pregnancies.
Why the study?
Preeclampsia is a major cause of maternal and neonatal illness and death, prompting an evaluation of the efficacy of low-dose aspirin for its prevention in high-risk pregnancies.
Does low-dose aspirin 81 mg daily prevent preeclampsia in high-risk pregnancies?
RCT (n=165)
Blinded (identical-looking placebo)
Randomly assigned
No
Does low-dose aspirin 81 mg daily prevent preeclampsia in high-risk pregnancies?
Low-dose aspirin (81 mg daily) initiated between 12-16 weeks of gestation significantly reduces the incidence of preeclampsia and improves neonatal outcomes in high-risk pregnancies.
Answers are grounded in this paper and cite their sources.
Supports low-dose aspirin initiation at 12-16 weeks in high-risk pregnancies; confirms preeclampsia prevention in this RCT.
Introduction: Preeclampsia is a major cause of illness and death for pregnant women and newborns worldwide, with an estimated prevalence ranging from 2% to 15% of all pregnancies, with an average of approximately 4.6%. Objective: The study's main objective is to find the efficacy of low-dose aspirin in preventing preeclampsia in high-risk pregnancies. Methodology: This randomized control trial was conducted at Shalamar Hospital, Lahore during 1st June 2024 to 31st Nov 2024. Data were collected from 165 pregnant women. Participants were randomly assigned into two groups: the aspirin group, which received a daily dose of 81 mg low-dose aspirin, and the placebo group, which received an identical-looking placebo. Results: Data were collected from 165 patients. Maternal age was 30.5 ± 4.2 years in the aspirin group and 31.0 ± 4.0 years in the placebo group (p = 0.48). Gestational age at enrolment averaged 13.8 ± 1.2 weeks and 13.7 ± 1.3 weeks for the aspirin and placebo groups, respectively (p = 0.65). BMI was 29.5 ± 3.8 kg/m² in the aspirin group and 29.8 ± 3.5 kg/m² in the placebo group (p = 0.72). Key risk factors, such as chronic hypertension (20% vs. 22%, p = 0.76) and history of preeclampsia (18% vs. 20%, p = 0.68), were evenly distributed. The mean gestational age at delivery was significantly higher in the aspirin group (38.2 ± 1.5 weeks) compared to the placebo group (36.8 ± 2.0 weeks). Conclusion: It is concluded that low-dose aspirin is an effective and safe intervention for preventing preeclampsia in high-risk pregnancies.
No takes yet. Share an insight, caveat, or question.
Zulfiqar et al. (2025) conducted an RCT in High-risk pregnancy (n=165). Low-dose aspirin vs. Placebo was evaluated on Gestational age at delivery. Low-dose aspirin increased mean gestational age at delivery compared to placebo in women with high-risk pregnancies.
Synapse has enriched 10 related papers. Consider them for comparative context: